



(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/EP2013/066425

(22) International Filing Date:
5 August 2013 (05.08.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12305975.0 6 August 2012 (06.08.2012) EP

(71) Applicants: **INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)** [FR/FR]; 101, rue de Tolbiac, F-75013 Paris (FR). **UNIVERSITE PARIS DESCARTES** [FR/FR]; 12, rue de l'Ecole de Médecine, F-75006 Paris 6 (FR). **ASSISTANCE PUBLIQUE HOPITAUX DE PARIS** [FR/FR]; 3, avenue Victoria, F-75004 Paris (FR).

(72) Inventors: **GALON, Jérôme**; INSERM U872, Team 15, Cordeliers, Research Center, 15 rue de l'Ecole de Médecine, F-75006 Paris (FR). **PAGES, Franck**; INSERM U872, Team 15, Cordeliers, Research Center, 15 Rue de l'Ecole de Médecine, F-75006 Paris (FR). **MLECNIK, Bernhard**; INSERM U872, Team 15, Cordeliers, Research Center, 15 Rue de l'Ecole de Médecine, F-75006 Paris (FR). **BINDEA, Gabriela**; INSERM U872, Team 15, Cordeliers, Research Center, 15 rue de l'Ecole de Médecine, F-75006 Paris (FR).

(74) Agents: **PERIN, Georges** et al.; Cabinet Plasseraud, 52 rue de la Victoire, F-75440 Paris Cedex 09 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHODS AND KITS FOR SCREENING PATIENTS WITH A CANCER

(57) Abstract: A method for screening patients with a cancer comprising i) determining in a tumor sample obtained from a patient an expression level ELA₁ - ELA_n of one or several genes GA₁ - GA_n representative of human adaptive immune response and an expression level ELI₁ - ELI_n of one or several genes GI₁ - GI_n representative of human immunosuppressive response, ii) comparing the expression levels ELA₁ - ELA_n and ELI₁ - ELI_n determined at step i) with predetermined reference values ELRA₁ - ELRA_n and ELRI₁ - ELRI_n selected such as said predetermined reference values separate a panel of patients with a cancer into two groupings according to the expression level of said genes and to survival of patients according to Kaplan Meier curves analyses and associated log-rank p values iii) concluding whether the patient has a good (level higher than the predetermined reference value) or a bad (level lower than the predetermined reference value) adaptive immune response and a good or a bad immunosuppressive response, optionally further comprising a step of concluding that a patient would or would not advantageously receive an antitumoral treatment, a kit comprising components for implementing step i) and a chemotherapeutic agent, an immunotherapeutic agent or a radiotherapeutic agent for use in the treatment of a cancer patient who is considered as responder to antitumoral treatment according to the method.

